**Name of Journal:** *World Journal of Gastrointestinal Endoscopy*

**Manuscript NO:** 45623

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Cohort Study***

**Age, socioeconomic features, and clinical factors predict receipt of endoscopic retrograde cholangiopancreatography in pancreatic cancer**

Rustgi SD *et al.* Variations in ERCP use for pancreatic cancer

Sheila D Rustgi, Sunil P Amin, Michelle K Kim, Satish Nagula, Nikhil A Kumta, Christopher J DiMaio, Paolo Boffetta, Aimee L Lucas

**Sheila D Rustgi, Michelle K Kim, Satish Nagula, Nikhil A Kumta, Christopher J DiMaio, Aimee L Lucas,** Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States

**Sunil P Amin**, Division of Gastroenterology, Virginia Mason Medical Center, Seattle, WA 98101, United States

**Paolo Boffetta,** Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States

**ORCID number:** Sheila D Rustgi (0000-0002-1889-1652); Sunil P Amin (0000-0002-3067-4730); Michelle K Kim (0000-0001-5285-8218); Satish Nagula (0000-0003-4519-7276); Nikhil A Kumta (0000-0002-8090-7846); Christopher J DiMaio (0000-0003-4775-4945); Paolo Boffetta (0000-0002-3811-2791); Aimee L Lucas (0000-0003-0341-4826).

**Author contributions:** Rustgi SD, Amin SP and Lucas AL contributed to study conception and design; Rustgi SD, Amin SP and Lucas AL contributed to data acquisition, data analysis and interpretation, and writing of article; Rustgi SD, Amin SP, Kim MK, Nagula S, Kumta NA, DiMaio CJ, Boffetta P and Lucas AL contributed to editing, reviewing and final approval of article.

**Supported by** American Cancer Society Grant, No. 129387-MRSG-16-015-01-CPHPS (to Lucas AL).

**Institutional review board statement:** This study was approved by the Mount Sinai Hospital Institutional Review Board and the National Cancer Institute.

**Conflict-of-interest statement:** None.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Aimee L Lucas, MD, MSc, Associate Professor,** Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1069, New York, NY 10029, United States. aimee.lucas@mssm.edu

**Telephone:** +1-212-2410101

**Fax:** +1-646- 5378647

**Received:** January 14, 2019

**Peer-review started:** January 14, 2019

**First decision:** January 21, 2019

**Revised:** February 1, 2019

**Accepted:** February 13, 2019

**Article in press:** February 13, 2019

**Published online:** February 16, 2019

**Abstract**

***BACKGROUND***

Endoscopic retrograde cholangiopancreatography (ERCP) is the recommended technique for biliary decompression in pancreatic cancer. Previous studies have suggested racial, socioeconomic and geographic differences in diagnosis, treatment and outcomes of pancreatic cancer patients.

***AIM***

To examine geographic, racial, socioeconomic and clinical factors associated with utilization of ERCP.

***METHODS***

Surveillance, Epidemiology and End Results and linked Medicare claims data were used to identify pancreatic cancer patients between 2000-2011. Claims data were used to identify patients who had ERCP and other treatments. The primary outcome was receipt of ERCP. Chi-squared analyses were used to compare demographic information. Trends in use of ERCP over time were assessed using Cochran Armitage test. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for receipt ERCP were calculated using logistic regression, controlling for other characteristics.

***RESULTS***

Among 32510 pancreatic cancer patients, 14704 (45.2%) underwent ERCP. Patients who had cancer located in the head of the pancreas (aOR 3.27, 95%CI: 2.99-3.57), had jaundice (aOR 7.59, 95%CI: 7.06-8.17), cholangitis (aOR 4.22, 95%CI: 3.71-4.81) or pruritus (aOR 1.42, 95%CI: 1.22-1.66) and lived in lower education zip codes (aOR 1.14, 95%CI: 1.04-1.24) were more likely to receive ERCP. In contrast, patients who were older (aOR 0.88, 95%CI: 0.83, 0.94), not married (aOR 0.92, 95%CI: 0.86, 0.98), and lived in a non-metropolitan area (aOR 0.89, 95%CI: 0.82, 0.98) were less likely to receive ERCP. Compared to white patients, non-white/non-black patients (aOR 0.83, 95%CI: 0.70-0.97) were less likely to receive ERCP. Patients diagnosed later in the study period were less likely to receive ERCP (aOR 2004-2007 0.85, 95%CI: 0.78-0.92; aOR 2008-2011 0.76, 95%CI: 0.70-0.83). After stratifying by indications for ERCP including jaundice, racial differences persisted (aOR black patients 0.80, 95%CI: 0.67-0.95, nonwhite/nonblack patients 0.73, 95%CI: 0.58-0.91). Among patients with jaundice, those who underwent surgery were less likely to undergo ERCP (aOR 0.60, 95%CI: 0.52, 0.69).

***CONCLUSION***

ERCP utilization in pancreatic cancer varies based on patient age, marital status, and factors related to where the patient lives. Further studies are needed to guide appropriate biliary intervention for these patients.

**Key words:** Pancreatic cancer; Endoscopic retrograde cholangiopancreatography; Socioeconomic disparities; Racial disparities; Jaundice; Outcomes research

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The use of endoscopic retrograde cholangiopancreatography for pancreatic cancer patients varies nationally by non-clinical factors. Further studies and guidelines are needed to guide appropriate biliary interventions for these patients.

**Citation**: Rustgi SD, Amin SP, Kim MK, Nagula S, Kumta NA, DiMaio CJ, Boffetta P, Lucas AL. Age, socioeconomic features, and clinical factors predict receipt of endoscopic retrograde cholangiopancreatography in pancreatic cancer. *World J Gastrointest Endosc* 2019; 11(2): 133-144

**URL:** https://www.wjgnet.com/1948-5190/full/v11/i2/133.htm

**DOI:** https://dx.doi.org/10.4253/wjge.v11.i2.133

**INTRODUCTION**

Pancreatic cancer is the fourth most common cause of cancer death in the United States[1]. Endoscopic retrograde cholangiopancreatography (ERCP), especially prior to widespread use of endoscopic ultrasound (EUS), served both diagnostic and therapeutic roles in the evaluation and management of pancreatic cancer[2,3]. ERCP is recommended to relieve biliary obstruction in pancreatic cancer[3,4].

Although pancreatic cancer outcomes are poor for the general population, several studies have shown that racial and sociodemographic factors impact use of treatment and overall survival[5-12]. A recent retrospective study of the Surveillance, Epidemiology and End Results (SEER)-Medicare population found that sociodemographic factors were associated with receipt of pancreatic cancer-directed surgery, but that only geographic location was independently associated with survival[13]. Other studies suggest black patients fare worse than white patients in both utilization of pancreatic cancer treatment modalities and survival[7,10-12].

Since previous studies have demonstrated racial, socioeconomic, geographic and clinical disparities in pancreatic cancer-directed surgery, chemotherapy and radiation, we hypothesized similar variations may be seen in the use of ERCP. The aim of this study is to evaluate racial, socioeconomic, geographic and clinical factors associated with use of ERCP among patients with pancreatic cancer. A secondary outcome was receipt of ERCP in the setting of jaundice, cholangitis or pruritus.

**MATERIALS AND METHODS**

***Patient selection and treatment***

The SEER database of the National Cancer Institute is a national registry of patients diagnosed with cancer that collects data on cancer incidence and survival[14]. This database is linked with the patient’s Medicare claims from time of Medicare eligibility until death. The claims were used to identify patients’ clinical and procedural data. Patients in this study population are aged 65 and older because this is the age of enrollment in Medicare coverage in the United States. Patients with secondary insurance were excluded so that all claims were captured in this dataset. Patients with primary pancreatic cancer diagnosed between 2000 and 2011 were identified; those patients with more than one primary cancer were excluded to eliminate the effect of other cancers on morbidity and mortality[15].

Sociodemographic information was obtained from both the SEER and Medicare-linked databases. Comorbid conditions were controlled for using the Deyo adaption of the Charlson co-morbidity index[16-18]. Both inpatient and outpatient hospital claims (Medicare Provider Analysis and Review, Outpatient Standard Analytical File) as well as diagnoses on claims submitted by individual physicians (Carrier file) were included[18,19].

Education and income information was obtained from census data. Patients’ zip codes were cross-referenced with census data to obtain median incomes for the zip code. Similarly, zip codes and census data were used to identify the proportion of residents in the zip code who had not completed high school, graduated from high school, attained some college and graduated from college. Patient level income and education data are not available.

ERCP, surgery, chemotherapy, radiation, jaundice, pruritus and cholangitis were identified from claims data using International Classification of Disease, 9th Edition and Healthcare Common Procedure Coding System codes (Table 1)[20-23]. SEER-Medicare claims have been shown to accurately capture patients who have been treated with chemotherapy[23]. SEER historic stage was used for patient stage because American Joint Committee on Cancer stage was only available from 2004 to 2011. Patients of all stages were included in this analysis because all of these patients are evaluated for and receive these procedures.

***Statistical analysis***

Categorical variables were compared using chi-squared analyses to test for associations between patients’ racial, socioeconomic, geographic and clinical characteristics and use ERCP. Statistical significance was noted as *P* value < 0.05. Trends in use of ERCP over time were assessed using Cochran Armitage test. Adjusted odds ratios and 95% confidence intervals (CIs) for receipt ERCP were calculated using logistic regression, controlling for other characteristics, including age, race, marital status, education, income, metropolitan area, region of the United States, symptoms and conditions, Charlson comorbidity scores, cancer site, stage and use of other therapies including surgery, chemotherapy and radiation. All statistical analyses were performed using SAS 9.3 and 9.4 (Cary, NC). The study was approved by both the local Institutional Review Board and the National Cancer Institute.

**RESULTS**

Between 2000 and 2011, a total of 32510 patients were diagnosed with pancreatic cancer and met inclusion criteria (Figure 1 and Table 2). Among these patients, 14704 (45.2%) underwent ERCP. Patients who underwent ERCP were more often younger (46.9% vs 43.9%, *P* < 0.01), married (46.3% *vs* 44.2%, *P* < 0.01), and white (45.8% white *vs* 42.3% of black patients vs 42.7% of non-white/non-black patients, *P* < 0.01) (Table 2). ERCP was used less often later in the study period (Table 3, Cochran-Armitage trend *P* < 0.01). More patients in the Northeast underwent ERCP (46.5%) compared to Southeast (45.4%), Midwest (43.3%) or West Coast (45.1%), *P* < 0.01 (Table 2). More patients with jaundice (78.1%), cholangitis (87.4%) and pruritus (70.8%) underwent ERCP than those without these symptoms, *P* for all < 0.01. Patients who underwent other cancer directed therapies including chemotherapy, radiation and surgery also received ERCP more often.

To better assess the differences in receipt of ERCP, logistic regression was used to evaluate the impact of race, sociodemographic and clinical factors (Table 4). Patients who were older (aOR 0.88, 95%CI: 0.82-0.95), not married (aOR 0.90, 95%CI: 0.85-0.97), or lived in a non-metropolitan area (aOR 0.87, 95%CI: 0.79-0.97) were less likely to receive ERCP. Compared to white patients, non-white/non-black patients (aOR 0.83, 95%CI: 0.70-0.97) were less likely to receive ERCP.

Clinical factors including cancer site, stage of cancer and use of other therapies were also associated with receipt of ERCP. Patients with cancer originating in the head of the pancreas had greater odds of receiving ERCP (aOR 3.27, 95%CI: 2.99-3.57) (Table 4). Compared to those with localized disease, patients with distant disease were less likely to receive ERCP (OR 0.52, 95%CI: 0.46-0.58). Finally, those who received chemotherapy (aOR for 1.39, 95%CI: 1.28-1.51) and radiation (aOR 1.21, 95%CI: 1.11-1.33) had increased odds of receiving ERCP. Those who underwent surgery were less likely to receive ERCP (aOR 0.82, 95%CI: 0.73-0.92). Charlson score did not impact receipt of ERCP.

ERCP may not always be indicated in pancreatic cancer, and receipt of biliary decompression may not always suggest appropriate management. To address this, we performed a stratified analysis for receipt of ERCP in the setting of jaundice, cholangitis and pruritus (Table 5). After stratifying by indications for ERCP, racial differences became apparent. Compared to white patients, black patients (aOR 0.80, 95%CI: 0.67-0.95) and non-white/non-black (aOR 0.73, 95%CI: 0.58-0.91) were less likely to undergo ERCP in the presence of jaundice (Table 5). Among patients with jaundice, patients who underwent surgery were less likely to undergo ERCP (aOR 0.60, 95%CI: 0.52-0.69).

The use of ERCP decreased over time: 4955 (47.7%) of patients received ERCP in 2000-2003, 4949 (44.5%) in 2004-2007, and 4800 (43.7%) in 2008-2011 (*P*-value for trend < 0.05, Table 3). Compared to those diagnosed early in the study, patients diagnosed in 2008-2011 were less likely to undergo ERCP (aOR 0.90, 95%CI: 0.83-0.97) (Table 4).

**DISCUSSION**

To our knowledge, this is the first study to evaluate race, income, education, geographic location and other clinical and sociodemographic characteristics in receipt ERCP in pancreatic cancer. While not curative, endoscopic procedures aid with diagnosis and staging, alleviate morbidity and facilitate other curative treatments including surgery and chemotherapy[3]. Given the dismal prognosis associated with pancreatic cancer, it is important to ensure that all patients have access to procedures that can aid in diagnosis, staging and management to reduce disparities in outcomes.

While other analyses have focused on racial disparities in PC, our study is unique in its ability to capture other sociodemographic data, such as income and education[5-10,13,24,25]. When controlling for these factors, we found no differences in overall receipt of ERCP for black patients. In our analyses stratified by ERCP indications, black patients received ERCP less often for jaundice, but not cholangitis or pruritus. In contrast, non-white/non-black patients received ERCP less often for the indications of jaundice and cholangitis, but not pruritus. Given the relatively small number of patients with pruritus (*n* = 146 for black patients and *n* = 120 for non-black/non-white patients), it is possible the sample is not sufficient to detect differences in use of ERCP for pruritic patients. Further studies are warranted to investigate these racial discrepancies.

Interestingly, patient age, marital status, and factors related to where the patient lives, including metropolitan area, were also associated with receipt of ERCP in pancreatic cancer. The relationship between surgical resection and sociodemographic factors including younger age and being married has previously been shown; our findings suggest the same is true for ERCP[13]. Differences in utilization may be explained by access to experts available to perform these procedures and regional practice differences. It should be noted that geographic differences shown in this study may not be representative of all regions in the country, since the SEER registry includes a selected 19 urban and rural regions throughout the United States. The Charlson score was not associated with use of ERCP, suggesting patient comorbidities do not deter endoscopists from pursuing these procedures.

The use of ERCP in pancreatic cancer patients fell during this time period. This may reflect two trends: One is the use of EUS for diagnosis and staging generally supplanted ERCP during this time[3]. The second may have been a large randomized controlled trial that suggested that ERCP performed prior to surgical resection increased postoperative complications and surgical morbidity[26]. Both trends may have had an effect of decreasing the use of ERCP in pancreatic cancer.

Patients with advanced stage disease received ERCP less often than those without metastatic disease. These findings may be expected in patients pursuing palliative options or who chose to forego further diagnostic work up and treatment. In contrast, patients with regional disease were more likely to pursue ERCP, which may be consistent with a plan of care to pursue cure with other cancer directed therapies[27]. Multivariable analysis also showed that those who received chemotherapy and radiation were more likely to receive ERCP. ERCP can facilitate these treatments through biliary decompression and normalization of bilirubin. In contrast patients who underwent surgery were less likely to receive ERCP. During this time period, studies suggested that preoperative ERCP may increase postoperative complications, which may have impacted practice patterns[21,26].

There are several limitations to this study. There is variation in use of ERCP for malignant obstruction which may be guided by physician preference or protocols at different centers, which could not be measured through this database[28]. The use of ERCP in pancreatic cancer patients with resectable disease is controversial[29]. Additionally, receipt of ERCP in pancreatic cancer may not accurately reflect access to expert care or appropriate clinical care. To address this, we performed additional analyses stratified by clinical indications (jaundice, cholangitis and pruritus) for ERCP. Racial, socioeconomic and geographic disparities identified here point to the need for future studies on how best to use ERCP in the management of PC as well as how to ensure that all patients have access to high quality care.

This is an analysis of a retrospective claims database and therefore patients are not randomized. However, our goal with this study was to examine how care is delivered in the real world. As with any claims database the information are limited to procedures and diagnoses as submitted by physicians. Previous studies suggest the accuracy of procedure coding (*e.g.*, for endoscopy and surgery) is high[30-32].However, important clinical information that impacts recommendations for surgery and procedures, including smoking status and laboratory values (*e.g*., bilirubin level, carcinoembryonic antigen, cancer antigen 19-9), is not available.

Despite these limitations, this is the first study of a large population dataset that describes racial, sociodemographic and geographic disparities in use of ERCP for patients with pancreatic cancer. Since appropriate staging and prompt referral for surgery is crucial for potential of cure for these patients, it is possible that differences in the use of endoscopic procedures may partially explain previously described racial disparities in survival as well. ERCP utilization in pancreatic cancer varies based on patient age, marital status, and factors related to where the patient lives. Further studies are needed to guide appropriate biliary intervention for these patients

**Article Highlights**

***Research background***

Endoscopic retrograde cholangiopancreatography (ERCP) is an important therapeutic procedure in the management of pancreatic cancer; before endoscopic ultrasound use was widespread, it also served an important diagnostic role. Variations in its use by patient and sociodemographic factors have not previously been described.

***Research motivation***

Variability in diagnosis, management and survival of pancreatic cancer by patient factors such as race are well described. However, national trends and variations in use of endoscopic procedures such as ERCP for pancreatic cancer have not previously been described. We hypothesized that there would be variations that may partially explain some of the disparities in outcomes.

***Research objectives***

We sought to describe variations in receipt of ERCP by patient factors including sociodemographic status, regional location in the country, clinical factors such as stage and comorbidities, and receipt of cancer directed therapies.

***Research methods***

This is a retrospective cohort study of Medicare claims data. Logistic regression was used to identify patient characteristics associated with the use of ERCP.

***Research results***

Fourteen thousand seven hundred and four patients diagnosed with pancreatic cancer underwent ERCP between 2000 and 2011. After multivariable analysis, we found multiple factors were associated with receipt of ERCP, including marital status, age, race, living in a non-metropolitan area, year of diagnosis. Even amongst patients with an indication for ERCP (jaundice, cholangitis, pruritus) there were racial differences in use of ERCP. Whether or not these differences contribute to differences in outcomes is a future area of study.

***Research conclusions***

These findings suggest that use of ERCP in this country varies with non-clinical factors, such as patient race and marital status. This is similar to previous studies which suggest that there are disparities in stage at diagnosis, use of surgery and chemotherapy by sociodemographic factors. It is unclear what impact, if any, this may have on important patient outcomes such as survival.

***Research perspectives***

Further studies are needed to identify whether use of endoscopy in pancreatic cancer impacts outcomes, such as survival, and to guide appropriate use of biliary interventions in patients with pancreatic cancer.

**REFERENCES**

1 **Siegel RL**, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin* 2017; **67**: 7-30 [PMID: 28055103 DOI: 10.3322/caac.21387]

2 **Tempero MA**, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB 3rd, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA; National Comprehensive Cancer Networks. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. *J Natl Compr Canc Netw* 2012; **10**: 703-713 [PMID: 22679115 DOI: 10.1200/JCO.2013.48.7546]

3 **ASGE Standards of Practice Committee**, Eloubeidi MA, Decker GA, Chandrasekhara V, Chathadi KV, Early DS, Evans JA, Fanelli RD, Fisher DA, Foley K, Hwang JH, Jue TL, Lightdale JR, Pasha SF, Saltzman JR, Sharaf R, Shergill AK, Cash BD, DeWitt JM. The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia. *Gastrointest Endosc* 2016; **83**: 17-28 [PMID: 26706297 DOI: 10.1016/j.gie.2015.09.009]

4 **Isenberg G**, Gouma DJ, Pisters PW. The on-going debate about perioperative biliary drainage in jaundiced patients undergoing pancreaticoduodenectomy. *Gastrointest Endosc* 2002; **56**: 310-315 [PMID: 12173585 DOI: 10.1067/mge.2002.126146]

5 **Abraham A**, Al-Refaie WB, Parsons HM, Dudeja V, Vickers SM, Habermann EB. Disparities in pancreas cancer care. *Ann Surg Oncol* 2013; **20**: 2078-2087 [PMID: 23579872 DOI: 10.1245/s10434-012-2843-z]

6 **Chang KJ**, Parasher G, Christie C, Largent J, Anton-Culver H. Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups. *Cancer* 2005; **103**: 349-357 [PMID: 15593353 DOI: 10.1002/cncr.20771]

7 **Khawja SN**, Mohammed S, Silberfein EJ, Musher BL, Fisher WE, Van Buren G 2nd. Pancreatic cancer disparities in African Americans. *Pancreas* 2015; **44**: 522-527 [PMID: 25872128 DOI: 10.1097/MPA.0000000000000323]

8 **Lim JE**, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. *Ann Surg* 2003; **237**: 74-85 [PMID: 12496533 DOI: 10.1097/00000658-200301000-00011]

9 **Riall TS**, Townsend CM Jr, Kuo YF, Freeman JL, Goodwin JS. Dissecting racial disparities in the treatment of patients with locoregional pancreatic cancer: a 2-step process. *Cancer* 2010; **116**: 930-939 [PMID: 20052726 DOI: 10.1002/cncr.24836]

10 **Singal V**, Singal AK, Kuo YF. Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis. *J Cancer Res Clin Oncol* 2012; **138**: 715-722 [PMID: 22246279 DOI: 10.1007/s00432-012-1156-8]

11 **Wray CJ**, Castro-Echeverry E, Silberfein EJ, Ko TC, Kao LS. A multi-institutional study of pancreatic cancer in Harris County, Texas: race predicts treatment and survival. *Ann Surg Oncol* 2012; **19**: 2776-2781 [PMID: 22526908 DOI: 10.1245/s10434-012-2361-z]

12 **Zeng C**, Wen W, Morgans AK, Pao W, Shu XO, Zheng W. Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. *JAMA Oncol* 2015; **1**: 88-96 [PMID: 26182310 DOI: 10.1001/jamaoncol.2014.161]

13 **Shapiro M**, Chen Q, Huang Q, Boosalis VA, Yoon CH, Saund MS, Whang EE, Gold JS. Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer. *JAMA Surg* 2016; **151**: 338-345 [PMID: 26581025 DOI: 10.1001/jamasurg.2015.4239]

14 **National Cancer Institute**. Overview of the SEER Program. Accessed June 23, 2017. Available from: URL: http://seer.cancer.gov/about/overview.html

15 **Amin S**, Mhango G, Lin J, Aronson A, Wisnivesky J, Boffetta P, Lucas AL. Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis. *Am J Gastroenterol* 2016; **111**: 1350-1357 [PMID: 27430290 DOI: 10.1038/ajg.2016.288]

16 **Charlson ME**, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987; **40**: 373-383 [PMID: 3558716 DOI: 10.1016/0021-9681(87)90171-8]

17 **Deyo RA**, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 1992; **45**: 613-619 [PMID: 1607900 DOI: 10.1016/0895-4356(93)90104-9]

18 **Klabunde CN**, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. *J Clin Epidemiol* 2000; **53**: 1258-1267 [PMID: 11146273 DOI: 10.1016/S0895-4356(00)00256-0]

19 **Klabunde CN**, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. *Med Care* 2006; **44**: 921-928 [PMID: 17001263 DOI: 10.1097/01.mlr.0000223480.52713.b9]

20 **Parmar AD**, Vargas GM, Tamirisa NP, Sheffield KM, Riall TS. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. *Surgery* 2014; **156**: 280-289 [PMID: 24851723 DOI: 10.1016/j.surg.2014.03.001]

21 **Jinkins LJ**, Parmar AD, Han Y, Duncan CB, Sheffield KM, Brown KM, Riall TS. Current trends in preoperative biliary stenting in patients with pancreatic cancer. *Surgery* 2013; **154**: 179-189 [PMID: 23889947 DOI: 10.1016/j.surg.2013.03.016]

22 **Saleh MM**, Nørregaard P, Jørgensen HL, Andersen PK, Matzen P. Preoperative endoscopic stent placement before pancreaticoduodenectomy: a meta-analysis of the effect on morbidity and mortality. *Gastrointest Endosc* 2002; **56**: 529-534 [PMID: 12297769 DOI: 10.1067/mge.2002.128161]

23 **Warren JL**, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB. Utility of the SEER-Medicare data to identify chemotherapy use. *Med Care* 2002; **40**: IV-55-61 [PMID: 12187169 DOI: 10.1097/01.MLR.0000020944.17670.D7]

24 **Amin S**, Lucas AL, Frucht H. Evidence for treatment and survival disparities by age in pancreatic adenocarcinoma: a population-based analysis. *Pancreas* 2013; **42**: 249-253 [PMID: 22836862 DOI: 10.1097/MPA.0b013e31825f3af4]

25 **Murphy MM**, Simons JP, Ng SC, McDade TP, Smith JK, Shah SA, Zhou Z, Earle CC, Tseng JF. Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma. *Ann Surg Oncol* 2009; **16**: 2968-2977 [PMID: 19669839 DOI: 10.1245/s10434-009-0656-5]

26 **van der Gaag NA**, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ, Gerritsen JJ, Greve JW, Gerhards MF, de Hingh IH, Klinkenbijl JH, Nio CY, de Castro SM, Busch OR, van Gulik TM, Bossuyt PM, Gouma DJ. Preoperative biliary drainage for cancer of the head of the pancreas. *N Engl J Med* 2010; **362**: 129-137 [PMID: 20071702 DOI: 10.1056/NEJMoa0903230]

27 **Fogel EL**, Shahda S, Sandrasegaran K, DeWitt J, Easler JJ, Agarwal DM, Eagleson M, Zyromski NJ, House MG, Ellsworth S, El Hajj I, O'Neil BH, Nakeeb A, Sherman S. A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. *Am J Gastroenterol* 2017; **112**: 537-554 [PMID: 28139655 DOI: 10.1038/ajg.2016.610]

28 **Yang D**, Perbtani YB, An Q, Agarwal M, Riverso M, Chakraborty J, Brar TS, Westerveld D, Zhang H, Chauhan SS, Forsmark CE, Draganov PV. Survey study on the practice patterns in the endoscopic management of malignant distal biliary obstruction. *Endosc Int Open* 2017; **5**: E754-E762 [PMID: 28791325 DOI: 10.1055/s-0043-111592]

29 **Rustgi SD**, Amin S, Yang A, Kim MK, Nagula S, Kumta NA, DiMaio CJ, Boffetta P, Lucas AL. Preoperative Endoscopic Retrograde Cholangiopancreatography is not Associated With Increased Pancreatic Cancer Mortality. *Clin Gastroenterol Hepatol* 2018; **pii**: S1542-3565(18)31333-8 [PMID: 30529734 DOI: 10.1016/j.cgh.2018.11.056]

30 **Cooper GS**, Yuan Z, Stange KC, Amini SB, Dennis LK, Rimm AA. The utility of Medicare claims data for measuring cancer stage. *Med Care* 1999; **37**: 706-711 [PMID: 10424641 DOI: 10.1097/00005650-199907000-00010]

31 **Ko CW**, Dominitz JA, Green P, Kreuter W, Baldwin LM. Accuracy of Medicare claims for identifying findings and procedures performed during colonoscopy. *Gastrointest Endosc* 2011; **73**: 447-453.e1 [PMID: 20950800 DOI: 10.1016/j.gie.2010.07.044]

32 **Cooper GS**, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. *Med Care* 2002; **40**: IV-43-8 [PMID: 12187167 DOI: 10.1097/01.MLR.0000020943.21850.F1]

**P-Reviewer:** de Moura DTH, Hosoe N **S-Editor:** Ji FF **L-Editor:** A **E-Editor:** Tan WW

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 International Classification of Disease, 9th Edition and Healthcare Common Procedure Coding System codes for claims data**

|  |  |  |
| --- | --- | --- |
|  | **ICD-9** | **HCPCS** |
| Endoscopic ultrasound | NA | 76975, 43231, 43232, 43237, 43238, 43242, 43259 |
| Endoscopic retrograde cholangiopancreatography  | 51.10, 51.11, 51.84-51.87, 51.99, 52.13, 52.93 | 74328-74330, 43260-43269, 43271, 43272 |
| Surgery | 52.51, 52.6, 52.7 | 48150, 48152, 48153, 48154, 48155 |
| Jaundice | 782.4 | NA |
| Cholangitis  | 576.1 | NA |
| Pruritus  | 698.9 | NA |

NA: Not applicable; ICD-9: International Classification of Disease, 9th Edition; HCPCS: Healthcare Common Procedure Coding System.

**Table 2 Characteristics of patients with pancreatic cancer by receipt of endoscopic retrograde cholangiopancreatography *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Total**  | **Received ERCP**  | **No ERCP** | ***P* value** |
| **Total** | 32510 (100.0) | 14704 (45.2) | 17806 (54.8) |  |
| **Sex** |  |  |  | 0.49 |
| Male | 14147 (43.5) | 6368 (45.0) | 7779 (55.0) |  |
| Female | 18363 (56.5) | 8336 (45.4) | 10027 (54.6) |  |
| **Age** |  |  |  | < 0.01 |
| 65-75 | 14205 (43.7) | 6665 (46.9) | 7540 (53.1) |  |
| 76 + | 18305 (56.3) | 8039 (43.9) | 10266 (56.1) |  |
| **Marital status** |  |  |  | < 0.01 |
| Married | 15928 (49.0) | 7370 (46.3) | 8558 (53.7) |  |
| Not married | 16582 (51.0) | 7334 (44.2) | 9248 (55.8) |  |
| **Race** |  |  |  | < 0.01 |
| White | 27399 (84.3) | 12534 (45.8) | 14865 (54.3) |  |
| Black | 3349 (10.3) | 1418 (42.3) | 1931 (57.7) |  |
| Other | 1762 (5.4) | 752 (42.7) | 1010 (57.3) |  |
| **Year of diagnosis** |  |  |  | < 0.01 |
| 2000-2003 | 10388 (32.0) | 4955 (47.7) | 5433 (52.3) |  |
| 2004-2007 | 11134 (34.3) | 4949 (44.5) | 6185 (55.6) |  |
| 2008-2011 | 10988 (33.8) | 4800 (43.7) | 6188 (56.3) |  |
| **Residence** |  |  |  | 0.06 |
| Metropolitan  | 27161 (83.6) | 12346 (45.5) | 14815 (54.6) |  |
| Non-metropolitan | 5346 (16.5) | 2356 (44.1) | 2990 (55.9) |  |
| **SEER registry region** |  |  |  | < 0.01 |
| Northeast | 7153 (22.0) | 3326 (46.5) | 3827 (53.5) |  |
| Southeast | 8128 (25.0) | 3688 (45.4) | 4440 (54.6) |  |
| Midwest | 4243 (13.1) | 1835 (43.3) | 2408 (56.8) |  |
| West Coast | 12986 (39.9) | 5855 (45.1) | 7131 (54.9) |  |
| **Income (zip code)** |  |  |  | 0.96 |
| High income | 7948 (25.0) | 3591 (45.2) | 4357 (54.8) |  |
| Low income | 23841 (75.0) | 10780 (45.2) | 13061 (54.8) |  |
| **Education (zip code)** |  |  |  | 0.02 |
| Low education  | 10188 (32.0) | 4702 (46.2) | 5486 (53.9) |  |
| High education  | 21638 (68.0) | 9687 (44.8) | 11951 (55.2) |  |
| **SEER historic stage** |  |  |  | < 0.01 |
| Localized  | 3042 (9.4) | 1806 (59.4) | 1236 (40.6) |  |
| Regional  | 9178 (28.2) | 5946 (64.8) | 3232 (35.2) |  |
| Distant | 16846 (51.8) | 5170 (30.7) | 11676 (69.3) |  |
| Unstaged  | 3400 (10.5) | 1758 (51.7) | 1642 (48.3) |  |
| **Region of pancreas**  |  |  |  | < 0.01 |
| Head | 16670 (71.2) | 10710 (64.3) | 5960 (35.8) |  |
| Body/Tail | 6744 (28.8) | 1080 (16.0) | 5664 (84.0) |  |
| **Symptoms** |  |  |  |  |
| Jaundice | 14189 (43.7) | 11076 (78.1) | 3113 (21.9) | < 0.01 |
| Cholangitis | 3970 (12.2) | 3471 (87.4) | 499 (12.6) | < 0.01 |
| Pruritus | 1832 (5.6) | 1297 (70.8) | 535 (29.2) | < 0.01 |
| **Charlson Comorbidity score** |  |  |  | 0.12 |
| 0 | 14423 (46.6) | 6616 (45.9) | 7807 (54.1) |  |
| 1 | 9049 (29.3) | 4181 (46.2) | 4868 (53.8) |  |
| 2 | 3964 (12.8) | 1760 (44.4) | 2204 (55.6) |  |
| 3+ | 3487 (11.3) | 1550 (44.5) | 1937 (55.6) |  |
| **Therapeutic treatment** |  |  |  |  |
| Chemotherapy | 13235 (40.7) | 6679 (50.5) | 6556 (49.5) | < 0.01 |
| Radiation | 7298 (22.5) | 4198 (57.5) | 3100 (42.5) | < 0.01 |
| Surgery  | 3259 (10.0) | 2368 (72.7) | 891 (27.3) | < 0.01 |

Some lines do not sum to 100% due to rounding or missing data. Other race: Neither white nor black race. Not married includes single, divorced and widowed. Metropolitan area defined as counties in metropolitan areas with population of 250000 or more; urban area defined as counties with populations of 2500 or more, both adjacent to metropolitan areas and not adjacent to metropolitan areas; rural defined as counties either completely rural or with populations < 2500. High income defined as > 75th percentile of income, or $74147. Low income defined as < 75th percentile or $74147. High education defined as living in a zip code where > 50% of the population has completed some college or more. Low education is defined as living in a zip code where > 50% of the population has no college education. ERCP: Endoscopic retrograde cholangiopancreatography; SEER: Surveillance, Epidemiology and End Results.

**Table 3 Use of endoscopic retrograde cholangiopancreatography over time using Cochran Armitage trend *n* (%)**

|  | **Total** | **ERCP** | ***P* value** |
| --- | --- | --- | --- |
| **Year of diagnosis**  |  |  | < 0.01 |
| 2000-2003 | 10388 | 4955 (47.73) |  |
| 2004-2007 | 11134 | 4949 (44.45) |  |
| 2008-2011 | 10988 | 4800 (43.68) |  |
| Total | 32510 | 14704 (45.2) |  |

ERCP: Endoscopic retrograde cholangiopancreatography.

Table 4 Multivariable analysis of use of endoscopic retrograde cholangiopancreatography

|  | **Adjusted OR of receiving ERCP (95%CI)** |
| --- | --- |
| **Sex**  |  |
| Male | 1.00 (REF) |
| Female | 1.03 (0.96-1.11) |
| **Age** |  |
| 65-75  | 1.00 (REF) |
| 76+ | 0.88 (0.82-0.95) |
| **Marital status**  |  |
| Married  | 1.00 (REF) |
| Not married | 0.90 (0.85-0.97) |
| **Race** |  |
| White | 1.00 (REF) |
| Black | 0.92 (0.82-1.04) |
| Other | 0.83 (0.70-0.97) |
| **Education (zip code)** |  |
| > 50% high school only | 1.14 (1.04-1.24) |
| > 50% some college  | 1.00 (REF) |
| **Income (zip code)** |  |
| < 75th percentile | 1.10 (1.00-1.20) |
| > 75th percentile  | 1.00 (REF) |
| **Year of diagnosis** |  |
| 2000-2003 | 1.00 (REF) |
| 2004-2007 | 0.85 (0.78-0.92) |
| 2008-2011 | 0.76 (0.70-0.83) |
| **Metropolitan area** |  |
| Metropolitan area | 1.00 (REF) |
| Non-metropolitan area | 0.87 (0.79-0.97) |
| **United States region** |  |
| Southeast | 1.00 (REF) |
| Northeast | 1.07 (0.96-1.20) |
| Midwest | 0.96 (0.86-1.09) |
| West Coast | 1.03 (0.93-1.13) |
| **Comorbid conditions**  |  |
| Charlson score 0 | 1.00 (REF) |
| Charlson score 1 | 1.06 (0.98-1.15) |
| Charlson score 2 | 0.96 (0.86-1.07) |
| Charlson score 3+ | 0.99 (0.88-1.11) |
| **Cancer site** |   |
| Body or tail | 1.00 (REF) |
| Head of the Pancreas  | 3.27 (2.99-3.57) |
| **Symptoms1** |  |
| Jaundice | 7.59 (7.06-8.17) |
| Cholangitis  | 4.22 (3.71-4.81) |
| Pruritus | 1.42 (1.22-1.66) |
| **SEER historic stage**  |   |
| Localized | 1.00 (REF) |
| Regional | 1.01 (0.89-1.14) |
| Distant | 0.52 (0.46-0.58) |
| Unstaged  | 0.85 (0.73-1.00) |
| **Cancer directed therapies1** |
| Chemotherapy | 1.39 (1.28-1.51) |
| Radiation | 1.21 (1.11-1.33) |
| Surgery | 0.82 (0.73-0.92) |

1Referent category is not having those symptoms, conditions or treatments. Other race is neither white nor black race. Not married includes single, divorced and widowed. Metropolitan area defined as counties in metropolitan areas with population of 250000 or more. High income defined as > 75th percentile of income, or $74147. Low income defined as < 75th percentile or $74147. High education defined as living in a zip code where > 50% of the population has completed some college or more. Low education is defined as living in a zip code where > 50% of the population has no college education. OR: Odds ratio; CI: Confidence interval; Endoscopic retrograde cholangiopancreatography.

**Table 5 Analysis stratified by symptoms/conditions**

|  | **Adjusted OR of receiving ERCP (95%CI), amongst patients with Jaundice** | **Adjusted OR of receiving ERCP (95%CI), amongst patients with Cholangitis** | **Adjusted OR of receiving ERCP (95%CI), amongst patients with Pruritus** |
| --- | --- | --- | --- |
| **Sex** |
| Male | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Female | 1.17 (1.05-1.30) | 0.99 (0.77-1.27) | 1.00 (0.75-1.33) |
| **Age** |
| 65-75 | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| 76+ | 0.98 (0.88-1.09) | 0.86(0.67-1.10) | 0.97 (0.73-1.29) |
| **Marital status** |
| Married | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Not married | 0.85 (0.76-0.94) | 0.97 (0.75-1.26) | 0.94 (0.70-1.26) |
| **Race** |
| White | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Black | 0.80 (0.67-0.95) | 0.87 (0.58-1.28) | 0.88 (0.52-1.51) |
| Other | 0.73 (0.58-0.91) | 0.64 (0.42-0.98) | 1.00 (0.59-1.70) |
| **Education (zip code)** |
| > 50% high school only | 1.00 (0.88-1.13) | 0.79 (0.59-1.06) | 1.23 (0.88-1.71) |
| > 50% some college | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| **Income (zip code)** |
| < 75th percentile | 1.13 (0.99-1.30) | 1.50 (1.12-2.01) | 0.84 (0.60-1.17) |
| > 75th percentile | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| **Year of diagnosis** |
| 2000-2003 | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| 2004-2007 | 0.97 (0.86-1.10) | 0.94 (0.70-1.26) | 0.96 (0.67-1.39) |
| 2008-2011 | 1.00 (0.88-1.13) | 1.02 (0.76-1.37) | 0.76 (0.54-1.06) |
| **Metropolitan area** |
| Metropolitan area | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Non-metropolitan area | 0.79 (0.68-0.91) | 1.30 (0.87 -1.95) | 0.83 (0.56-1.24) |
| **United States region** |
| Southeast | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Northeast | 0.94 (0.80-1.11) | 1.23 (0.83-1.83) | 0.73 (0.46-1.14) |
| Midwest | 0.91 (0.76-1.07) | 1.09 (0.71-1.69) | 1.01 (0.61-1.67) |
| West Coast | 0.95 (0.82-1.09) | 1.02 (0.72-1.43) | 0.75 (0.51-1.11) |
| **Comorbid conditions** |
| Charlson score 0 | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Charlson score 1 | 1.06 (0.94-1.20) | 1.24 (0.92-1.67) | 1.24 (0.90-1.70) |
| Charlson score 2 | 0.93 (0.80-1.09) | 0.69 (0.50-0.96) | 0.77 (0.52-1.16) |
| Charlson score 3+ | 0.98 (0.83-1.16) | 0.84 (0.58-1.21) | 1.14 (0.72-1.80) |
| **Cancer site** |
| Body or tail | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Head of the pancreas | 3.82 (3.23-4.50) | 2.92 (1.98-4.31) | 8.03 (5.57-11.56) |
| **SEER historic stage** |
| Localized | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) |
| Regional | 0.85 (0.71-1.01) | 0.79 (0.52-1.21) | 1.21 (0.80-1.82) |
| Distant | 0.51 (0.43-0.60) | 0.44 (0.29-0.66) | 0.83 (0.54-1.28) |
| Unstaged | 0.75 (0.60-0.94) | 0.46 (0.28-0.77) | 0.88 (0.47-1.65) |
| **Cancer directed therapies1** |
| Chemotherapy | 1.68 (1.48-1.90) | 1.578 (1.20-2.07) | 0.91 (0.66-1.26) |
| Radiation | 1.21 (1.06-1.39) | 1.25 (0.94-1.67) | 1.19 (0.86-1.64) |
| Surgery | 0.60 (0.52-0.69) | 0.48 (0.35-0.67) | 0.84 (0.5-1.20) |

1Referent category is not undergoing these treatments. OR: Odds ratio; CI: Confidence interval; Endoscopic retrograde cholangiopancreatography.



**Figure 1 Patient selection.**